Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To test whether interventions with putative lipopolysaccharide (LPS)-lowering effects including sevelamer and a synbiotic (Bifidobacterium longum+oligofructose) improve insulin sensitivity in subjects with obesity.
Methods: We randomized 22 lean and 28 human subjects with obesity to receive sevelamer, synbiotic, or placebo orally for 4 weeks. Peripheral insulin sensitivity was measured with an insulin clamp. Plasma cholesterol, endotoxemia markers, intestinal permeability, stool bacterial taxonomic content and plasma metabolites also were assessed.
Results: At baseline, subjects with obesity had lower insulin sensitivity and elevated plasma LDL-C concentrations. Sevelamer improved insulin sensitivity and lowered LDL-C in these subjects. Intestinal enrichment of had no effect on insulin sensitivity or lipids in either group. Markers of endotoxemia and intestinal permeability did not change with any intervention. Plasma metabolomics revealed that sevelamer increases several metabolites, many of them previously linked with positive changes in glucose and lipid metabolism, including biliary acids, amino acids (citrulline, betaine), NAD+ precursors (trigonelline) and xenobiotics (genistein, umbelliferone).
Conclusion: Sevelamer improves insulin sensitivity and LDL-C in subjects with obesity, but these effects are independent of changes in circulating LPS. Sevelamer increases the levels of multiple metabolites that collectively may mediate improvements in glucose homeostasis and lipids caused by this drug.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12262773 | PMC |
| http://dx.doi.org/10.1101/2025.06.23.25327556 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Changes in antral follicle dynamics following weight loss in women with polycystic ovary syndrome.
Hum Reprod
September 2025
Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA.
Study Question: Does weight loss from a hypocaloric dietary intervention improve antral follicle dynamics in women with PCOS?
Summary Answer: During a 3-month hypocaloric dietary intervention, women with PCOS who experienced clinically meaningful weight loss showed more organized antral follicle development including fewer recruitment events, but no change in the overall frequency of selection, dominance, or ovulation.
What Is Known Already: There is a spectrum of disordered antral follicle development in women with PCOS including excessive follicle recruitment and turnover, decreased frequency of selection and dominance, and failure of ovulation. Lifestyle intervention aimed at weight loss is recommended to improve metabolic health in women with PCOS yet benefits on ovarian follicle development and ovulation are unclear.
Hypoxia-induced impairments in fasting glucose are associated with acute mountain sickness severity during four days of residence at 4,300 m.
Am J Physiol Regul Integr Comp Physiol
September 2025
United States Army Research Institute of Environmental Medicine, Natick, MA, US.
Unlabelled: Insulin resistance has been associated with acute mountain sickness (AMS) risk, but the influence of active ascent is unclear.
Methods: Thirty-two unacclimatized Soldiers (23±4yr; 80±14 kg) were tested at baseline residence (BLR), hiked ~5 km (n=16) or were driven (n=16) to 4,300 m, and stayed for 4 days (~66 h). Venous blood was taken each morning at BLR and during high altitude (HA) exposure days 2-4 (HA2-4) and the evening on day 1 at HA (HA1).
Over-time changes in the prevalence of metabolic syndrome and its components among elderly population in Iran from 2016 to 2021; A nation-wide study.
PLoS One
September 2025
Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Background: The prevalence of Metabolic Syndrome (MetS) increases with aging, significantly contributing to the rising burden of non-communicable diseases (NCDs). This study aimed to investigate over-time changes in the prevalence of MetS and its components among the elderly population of Iran.
Methods: We analyzed data from the 2016 and 2021 national STEPwise approach to non-communicable disease risk factor Surveillance (STEPS) for participants aged ≥65 who completed all three survey steps (questionnaire-based assessments, physical measurements, and laboratory tests) with no missing data on MetS components.
Expression of long non-coding RNAs MALAT1, MEG3, and XIST in gestational diabetes mellitus: a cross-sectional study.
Acta Diabetol
September 2025
Department of Endocrinology & Metabolism, Medical College & Hospital, Kolkata, 88, College St. College Square, Kolkata, West Bengal, 700073, India.
Background And Aims: Gestational diabetes mellitus (GDM) is defined as glucose intolerance first identified during pregnancy that does not meet the criteria for overt diabetes. Its pathophysiology shares key features with type 2 diabetes mellitus (T2D), including insulin resistance and inflammation. Emerging evidence suggests that long non-coding RNAs (lncRNAs) are implicated in T2D.
View Article and Find Full Text PDFNovel Strategies to Conquer Residual Adiposity Risk in Cardiovascular Disease.
Curr Atheroscler Rep
September 2025
Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, USA.
Purpose Of Review: Despite major advances in the treatment and prevention of atherosclerotic cardiovascular disease (ASCVD), a substantial burden of residual risk remains Obesity has been redefined as a primary and independent drivers of cardiovascular morbidity and mortality warranting focused attention.
Recent Findings: Obesity is now recognized as a chronic disease and a central contributor to residual cardiovascular risk through mechanisms including systemic inflammation, insulin resistance, dyslipidemia, and endothelial dysfunction. This review addresses the limitations of conventional obesity management and highlights emerging pharmacological therapies targeting the underlying adiposopathy.